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Ln[DO3A-N-α-(pyrenebutanamido)propionate]
complexes: optimized relaxivity and NIR optical
properties†
M. F. Ferreira,a G. Pereira,a A. F. Martins,b,c C. I. O. Martins,b M. I. M. Prata,d S. Petoud,c
E. Toth,c P. M. T. Ferreira,a J. A. Martins*‡a and C. F. G. C. Geraldesb
We have proposed recently that the DO3A-N-α-(amino)propionate chelator and its amide conjugates are
leads to targeted, high relaxivity, safe contrast agents for magnetic resonance imaging. In this work we
illustrate further the expeditious nature and robustness of the synthetic methodologies developed by pre-
paring the DO3A-N-(α-pyrenebutanamido)propionate chelator. Its Gd3+ chelate retains the optimized
water exchange, high stability and inertness of the parent complex. The pyrene moiety imparts concen-
tration-dependent self-assembly properties and aggregation-sensitive fluorescence emission to the Gd3+
complex. The Gd3+ complex displays pyrene-centred fluorescence whilst the Yb3+ and Nd3+ complexes
exhibit sensitized lanthanide-centred near-infrared luminescence. The aggregated form of the complex
displays high relaxivity (32 mM−1 s−1, 20 MHz, 25 °C) thanks to simultaneous optimization of the rotational
correlation time and of the water exchange rate. The relaxivity is however still limited by chelate flexibility.
This report demonstrates that the DO3A-N-(α-amino)propionate chelator is a valuable platform for con-
structing high relaxivity CA using simple design principles and robust chemistries accessible to most
chemistry labs.
Introduction
Positron emission tomography (PET), single photon emission
correlated tomography (SPECT), magnetic resonance imaging
(MRI), ultra sound (US), and X-ray computerized axial tomo-
graphy (CAT) are imaging modalities used nowadays regularly
in hospitals for diagnostic and prognostic purposes.1 MRI has
become in recent years the most useful imaging modality in
the clinical setup. This results from its superb spatial resolu-
tion, use of non-ionizing radiation (radiofrequencies and mag-
netic fields), depth independent imaging and the possibility of
repeated imaging to offset the low detection sensitivity of MRI
which is intrinsic to the nuclear magnetic resonance phenom-
enon. Signal intensity differences in MRI (contrast) arise
mainly from intrinsic differences of the relaxation times (T1,2)
of the water protons of tissues. The contrast between normal
and diseased tissues can be dramatically improved by para-
magnetic contrast agents (CA) (Gd3+, Mn2+, stable nitroxide
radicals, iron oxide nanoparticles, etc.), which shorten the
relaxation times of the water protons.2 Relaxivity (r1,2), which is
the paramagnetic enhancement of water proton relaxation
rates R1,2 (R1,2 = 1/T1,2) normalized to 1 mM concentration,
measures CA efficacy.2,3 The currently used CAs for T1-
weighted MRI imaging are Gd3+ chelates of linear (DTPA-type)
or macrocyclic (DOTA-type) poly(aminocarboxylate) chelators.
†Electronic supplementary information (ESI) available: Size distribution in: (a)
volume (%); (b) intensity (%) for a GdL solution (5 mM, pH 7.0, 25 °C) at a con-
centration well above the cmc (0.6 mM) (Fig. S1); temperature dependence of the
water proton relaxivity for GdL (20 MHz, 1 mM, pH 6.0) (Fig. S2); pH dependence
of the water proton relaxivity for GdL (20 MHz, 1 mM, 25 °C) (Fig. S3); time evol-
ution of R1p(t )/R1p(0) (20 MHz, pH 7.1, 25 °C) for a 1.5 mM solution of GdL in
10 mM phosphate buffer without and with an equimolar amount of Zn2+
(Fig. S4); UV-Vis spectra for the free ligand L and the GdL complex (Fig. S5); fluo-
rescence spectra for the free ligand L in non-deoxygenated water (pH 7.0) over
the concentration range 5 × 10−5–5 × 10−3 mol dm−3 (λexc = 345 nm) (Fig. S6);
changes in ratio excimer/monomer emission (IE/IM) for ligand L as a function of
the ligand concentration (Fig. S7); best fit values for the fitting of the experi-
mental data of IExc/IMono vs. [GdL] (Table S1); biodistribution of
153SmL in Wistar
rats 1 and 24 hours after i.v. injection (Table S2); equations for the analysis of 1H
NMRD and 17O NMR data (Appendix 1). See DOI: 10.1039/c3dt52958d
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Due to its long electronic relaxation times and high paramag-
netism, Gd3+ efficiently enhances T1 relaxation, resulting in
signal intensity enhancement and bright images – positive
contrast.4 High relaxivity CA can lead to T1 reductions
sufficient to generate effective contrast at low doses. Moreover,
delivering CA to diseased areas can allow further dose
reduction. Effective contrast at low CA doses (CAs in clinical
use are normally used at a dose of 0.1 mmol kg−1) became
more important recently with the identification of the nephro-
genic systemic fibrosis (NSF) which is a debilitating and even
deadly condition associated with in vivo Gd3+ release from
Gd-based CAs.5 In fact, free (non-complexed) Gd3+ (and all the
other Ln3+ ions) are acutely toxic. Most NSF cases have been
associated with the use of Gd3+ DTPA-type complexes, particu-
larly Gd(DTPA-bis-amide) CA.6 Low thermodynamic stability
and kinetic lability, coupled to slow kidney clearance, results
in extensive complex demetallation in vivo.7 Macrocyclic,
DOTA-type Gd3+ complexes are generally considered safe given
their higher thermodynamic stability and kinetic inertness.8
Chelates displaying simultaneous optimization of the mole-
cular parameters that govern relaxivity, namely the rotational
correlation time (τR), the water exchange rate (kex = 1/τM) and
the electronic relaxation parameters, are expected to display
very high relaxivities.9 There are well established strategies for
tuning τR and kex into the optimal range to attain high relaxiv-
ities at intermediate fields relevant for clinical MRI. Tuning
the Gd3+ ion electronic relaxation parameters turns out to
be more challenging.10 Increasing the molecular weight of
chelates leads to longer rotational correlation times (τR)
(slower tumbling rates) enhancing CA relaxivity at intermediate
fields.
Self-assembly of amphiphilic chelates into micelle-type
supramolecular structures,11 non-covalent association with
serum albumin12 and covalent attachment of chelates to
macromolecular and nanoobjects (proteins,13 dendrimers,14
nanoparticles,15 viral capsules,16 quantum dots,17 etc.) are well
established strategies to tune τR. Replacement of an ethylene-
diamine by a propylenediamine bridge or a pendant acetate by
a propionate group on the DOTA and DTPA scaffolds enforces
steric compression around the water binding site on Gd3+ com-
plexes, leading to accelerated water exchange.11,18,19 A pendant
propionate group leads to water exchange rate enhancements
suitable for attaining high relaxivities at intermediate fields,
without compromising the thermodynamic and kinetic stabi-
lity of the chelates.18,20,21 Still, connecting linkers/spacers
permit fast local rotational motions of the immobilized che-
lates superimposed on global slow rotational motions of the
(entire) macromolecular object, resulting in suboptimal
effective rotational correlation times.11,15
Endowing targeted high relaxivity Gd3+ chelates with a fluo-
rescence reporting capability results in bimodal MRI/fluo-
rescence imaging agents. This approach has the potential to
improve CA performance: the high detection sensitivity of fluo-
rescence complements the low detection sensitivity of MRI,
whilst the depth independent properties of MRI complement
the limited light crossing into live tissues.22
Conjugates of metal chelate-fluorophores,23 quantum
dots,17,24 silica nanoparticles25,26 and other nanomaterials
functionalised with Gd3+ chelates have been described as
bimodal MRI/fluorescence imaging agents. The aggregation
sensitive fluorescence properties of the pyrene fluorophore27
make pyrene conjugates especially attractive as “responsive”
probes for structural,28 biochemical and cellular studies29 and
as chemical sensors.30 Moreover, pyrene has been used as an
antenna for sensitizing near infrared (NIR) emitting Ln3+ ions
(Yb3+, Nd3+ and Er3+) in DOTA and DTPA chelates.31,32
We have recently described methodologies for the synthesis
of the DO3A-N-(α-amino)propionate chelator and for preparing
its amide conjugates.18,21 Gd3+ complexes of those amide con-
jugates retain the optimal water exchange, high stability and
kinetic inertness of the parent complex.18 In this work we
describe the synthesis of the pyrenebutyric acid conjugate of
the DO3A-N-(α-amino)propionate chelator and its Ln3+ com-
plexes. The effect of self-assembly on the relaxivity and fluo-
rescence properties of the Gd[(DO3A-N-(α-pyrenebutanamido)-
propionate)] complex was studied by relaxometry and steady
state fluorescence. The potential of the pyrene moiety to sensi-
tize NIR emitting Ln3+ ions has also been addressed.
Results and discussion
Synthesis
The DO3A-N-(α-pyrenebutanamido)propionate chelator (L) was
synthesised following the (indirect) methodology proposed
before for amide conjugates of the DO3A-N-(α-amino)propio-
nate chelator (Scheme 1).21
Scheme 1 Synthetic pathway for the metal chelator DO3A-N-(α-pyrene-
butanamido)propionate (L) and its Ln3+ complexes LnL: (a) K2CO3/
MeCN; (b) i. TFA/DCM, ii. ethyl bromoacetate, K2CO3/MeCN; (c) i. Dowex
1X2-OH−, ii. elution with hydrochloric acid 0.1 M; (d) LnCl3·xH2O.
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The N-(α-pyrenebutanamido)propionate pendant group was
introduced, early on the synthesis, into the cyclen scaffold via
Michael addition of the dehydroalanine (Pyrene, Boc)-Δ-
AlaOMe reactive block (4). Synthetic block (4) was prepared in
2 steps in 70% overall yield following the procedure developed
by Ferreira and co-workers (Scheme 2).33
After removing the tert-butyloxycarbonyl protecting group
from the monoalkylated intermediate (6) with TFA, one pot
N-alkylation of the cyclen scaffold with ethyl bromoacetate
afforded prochelator 7. Alkaline deprotection of 7 with Dowex
1X2-OH− resin, followed by resin elution with diluted hydro-
chloric acid, afforded the DO3A-N-(α-pyrenebutanamido)-
propionate chelator (L) as hydrochloride in 30% overall yield
over 3 steps. Recently, Caravan and co-workers have reported a
similar pathway for the synthesis of conjugates of the DO3A-N-
(α-amino)propionate chelator.34 The synthesis of the DO3A-N-
(α-pyrenebutanamido)propionate chelator further supports the
use of the indirect pathway for amide conjugates of the DO3A-
N-(α-amino)propionate chelator.
Relaxometric studies of the GdL complex
The concentration dependence of the paramagnetic water
proton relaxation rate (R1p) was evaluated for GdL (20 MHz,
25 °C, pH 7.0) in the concentration range 0.05–5.0 mM (Fig. 1).
The paramagnetic longitudinal relaxation rate data vs.
[GdL] define two straight lines with different slopes. This be-
haviour is characteristic of chelate self-assembly in aqueous
solution, presumably into micelle-type structures, driven by
the hydrophobic effect.11 The break point gives an estimation
of the critical micelle concentration, cmc (0.60 ± 0.02 mM), for
GdL. Below the cmc, the complex is in a monomeric, non-
aggregated form in solution (eqn (1)). Above the cmc, it is
present in the form of aggregates as well as monomers whose
concentration corresponds to the cmc (eqn (2)). Rd1 is the dia-
magnetic contribution to the longitudinal relaxation rate (the
relaxation rate of pure water), rn.a1 (6.86 ± 0.03 mM
−1 s−1) rep-
resents the relaxivity of the free, non-aggregated Gd3+ chelate,
ra1 (33.11 ± 0.04 mM
−1 s−1) is the relaxivity of the micellar
(aggregated) form and CGd is the analytical Gd
3+
concentration.
R1p ¼ Robs1  Rd1 ¼ rn:a1  CGd ð1Þ
R1p ¼ Robs1  Rd1 ¼ ðrn:a1  ra1Þ  cmcþ ra1  CGd ð2Þ
The micellar nature of GdL above the cmc (5.0 mM, pH 7.0)
was confirmed by dynamic light scattering (DLS) analysis
(Fig. S1†). A bimodal intensity distribution, with the main
population of particles displaying an average radius of 1.7 nm
and a minor population exhibiting an average radius of 73 nm,
was obtained by DLS, resulting in a population weighted mean
hydrodynamic radius, expressed by the z-average parameter, of
49 nm. The temperature (Fig. S2†) and pH dependences
(Fig. S3†) of the paramagnetic water proton relaxation rate
were studied at 20 MHz. Transmetallation studies against Zn2+
ions were also performed to evaluate the kinetic inertness of
the complex (Fig. S4†). The temperature dependence study
strongly suggests that below 50 °C, the relaxivity is not limited
by slow water exchange. The pH-dependence and the trans-
metallation studies indicate that the GdL complex, like
its non-associating Gd[(DO3A-N-(α-benzoylamido)propionate)]
analogue, is stable towards protonation-assisted demetallation
and inert towards transmetallation with Zn2+.21
17O NMR and 1H NMRD studies
The magnetic field dependence of the longitudinal water
proton relaxivities (1H NMRD profiles) of GdL was recorded at
25 °C and 37 °C in the frequency range 0.01 to 80 MHz and at
concentrations below (Fig. 3) and above (Fig. 2c) the cmc. The
NMRD curves are influenced by many parameters, the most
important being the hydration number (q), the water exchange
rate (kex), the electron relaxation parameters (τv and Δ
2) and
the rotational correlation time (τR). The NMRD measurements
have been completed with 17O NMR data (Fig. 2a and b).
Indeed, from variable temperature 17O T2 measurements, one
can accurately determine the water exchange rate. The
rotational correlation time can be assessed by variable temp-
erature 17O T1 measurements. On the other hand, variable
Fig. 1 Concentration dependence of the paramagnetic water proton
longitudinal relaxation rate R1p = (R
obs
1 − Rd1) for GdL (20 MHz, 25 °C,
pH 7.0).
Scheme 2 Synthesis of the dehydroalanine (Pyrene, Boc)-Δ-AlaOMe
reactive block (4): (a) i. TEA 2 molar equivalents/MeCN, ii. DCC/HOBt; (b)
Boc2O, DMAP, dry MeCN.
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temperature measurements of the chemical shift difference
between bulk and bound water (Δωr) give an indication of the
q value.
The proton relaxation rates measured above the cmc rep-
resent the sum of the relaxivity contribution of the monomer
complex, present at a concentration equal to the cmc, and the
relaxivity contribution of the aggregated state. In order to
calculate the relaxivity of the aggregated form, the relaxivity
contribution of the monomer has been subtracted from the
relaxation rates measured above the cmc. These profiles
present the characteristic high field peak typical of slowly tum-
bling Gd3+ complexes. The 17O NMR measurements have been
performed at 5.0 mM concentration, largely above the cmc
(0.6 mM). Under these conditions, one can consider that the
rotational dynamics, as assessed by 17O T1 data, corresponds
to the micellar state. Therefore, the 17O NMR data have been
fitted together with the NMRD curves of the micellar state to
the Solomon–Bloembergen–Morgan theory by including the
Lipari–Szabo treatment for the description of the rotational
motion (Table 1).35 In this approach, two kinds of motion are
assumed to modulate the interaction causing the relaxation,
namely a rapid, local motion which lies in the extreme narrow-
ing limit and a slower, global motion.
We calculate therefore τg, the correlation time for the global
motion (common to the whole micelle), and τl, the correlation
time for the fast local motion, which is specific for the individ-
ual relaxation axis and thus related to the motion of the indi-
vidual Gd3+ chelate units. The generalized order parameter, S,
is a model-independent measure of the degree of spatial
restriction of the local motion, with S = 0 if the internal
motion is isotropic and S = 1 if the motion is completely
restricted.
It was assumed that the GdL complex has one inner sphere
water molecule (q = 1) like the low molecular weight amide
analogue Gd[(DO3A-N-(α-benzoylamido)propionate)]21 and the
parent amine Gd[(DO3A-N-(α-amino)propionate)].18 This
assumption was confirmed by the value obtained for the scalar
coupling parameter (A/ћ = −3.2 × 106 rad s−1).36
The NMRD curves of the monomer sample (0.3 mM) have
been analyzed by fixing the water exchange parameters (k298ex ,
ΔH‡) to those obtained from the 17O NMR data. In the fits, we
have fixed the rGdH distance to 3.10 Å and the distance of
closest approach of the bulk water protons to the Gd3+,
aGdH, to 3.65 Å. The diffusion constant has been fixed to
23 × 10−10 m2 s−1 and its activation energy to 20 kJ mol−1.
The NMRD profile for the monomeric form is characteristic
of low molecular weight complexes (Fig. 3). The relaxivity at
intermediate field (5.9 mM−1 s−1; 25 °C, 20 MHz) is dominated
by fast rotation in solution as indicated by the short τR value
obtained (116 ps). In contrast, above the cmc the NMRD
profile of GdL displays a hump at intermediate field, typical of
slow tumbling species (Fig. 2c).11,15,35
The relaxivity decreases with increasing temperature, indi-
cating that it is not limited by slow water exchange. The same
behaviour was previously observed for gold nanoparticles func-
tionalised with the analogous cysteine conjugate Gd[(DO3A-N-
(α-cystamido)propionate)].15 The water exchange rate on GdL is
similar to that reported for the low molecular weight amide
analogue Gd[(DO3A-N-(α-benzoylamido)propionate)]21 and
slightly higher than that reported for the parent Gd[(DO3A-N-
Fig. 2 Temperature dependence of (a) reduced longitudinal, T1r (■),
and transverse, T2r (▲), relaxation times and (b) chemical shifts (Δωr) of a
micellar aqueous solution of GdL at 11.7 T (5.0 mM, pH 7.0); (c) NMRD
profiles of the aggregated micellar state (2.5 mM, pH 7.0) at 25 °C (■)
and 37 °C (▲) after subtraction of the relaxation contribution of the
monomer form. The curves represent results from the simultaneous
fittings as described in the text.
Table 1 Best fit parameters obtained for the aggregated form of GdL
from the simultaneous analysis of the 17O NMR and 1H NMRD data and
for the monomer from NMRD dataa
Parameter Aggregated form Monomer
ΔH‡ [kJ mol−1] 21.5 ± 1.5 21.5
k298ex [10
7 s−1] 6.2 ± 0.5 6.2
τ298g [ps] 3780 ± 100 116 ± 5
τ298lO [ps] 930 ± 50 —
S2 0.24 ± 0.02 —
τ298lH /τlO
298 0.80 ± 0.05 —
Eg [kJ mol
−1] 25.4 ± 0.7 —
El [kJ mol
−1] 12 ± 1 24.3 ± 0.2
Δ2 [1020 s−1] 0.033 ± 0.004 0.38 ± 0.04
τ298v [ps] 53 ± 5 6.3 ± 0.5
A/ћ [106 rad s−1] −3.2 ± 0.4 —
a Parameters in italics have been fixed; τ298RO values from
17O T1 data.
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(α-amino)propionate)]18 complex (k298ex /107 = 6.2, 5.7 and
4.0 s−1, respectively). This value is in the ideal range for attain-
ing high relaxivities at intermediate magnetic fields relevant
for clinical applications.19
The Lipari–Szabo analysis of the longitudinal 1H and 17O
relaxation rates allows separating fast local rotational motions
of the chelate (τRl = 930 ps) from the global rotational corre-
lation time (τRg = 3780 ps) of the micellar aggregate. The value
of the order parameter for GdL (S2 = 0.24) is similar to those
calculated for amphiphilic DOTA-type complexes functiona-
lised with hexadecyl alkyl chains: Gd(DOTASAC18)37 and Gd
(DOTAMAP-En-C18)38 (S2 = 0.24 and 0.28, respectively) (Fig. 4
and Table 2).
Complexes functionalised with two long alkyl chains, Gd-
[(C18)2DOTAda)]
39 and Gd[(DOTA(GAC12)2)],
40 are character-
ised by substantially higher order parameters (S2 = 0.78 and
0.70, respectively). Tighter packing of the monomers and
double anchoring through adjacent sites into the micelle
structure restrict internal rotational movements of the
chelates.
Moreover, the complex Gd[(C18)2DOTAda)] functionalised
with two alkyl chains displays a much lower cmc value than
the complex Gd(DOTASAC18) functionalised with one alkyl
chain. In this respect, the GdL complex displays a relatively
high cmc value (0.6 vs. 0.06 and 0.004 mM for Gd-
[(C18)2DOTAda)] and Gd(DOTASAC18), respectively) reflecting
probably the aromatic nature of the pyrene lipophylic moiety
and the deviation of the overall shape of the conjugate from
the wedge-like geometry which would be ideal for micelle
formation.
The relaxivity displayed by the micellar form of GdL
(32 mM−1 s−1, 20 MHz, 25 °C) is substantially higher than that
shown by the Gd(DOTASAC18) and Gd(DOTAMAP-En-C18)
complexes (24.2 and 20.7 mM−1 s−1, respectively) and it is
similar to the relaxivity of the double chain chelates Gd-
[(C18)2DOTAda)] and Gd[(DOTA(GAC12)2)] (35 and 34.8 mM
−1
s−1, respectively). The high relaxivity of the double chain
chelates has been ascribed to restricted local motions of the
complex (S2 = 0.78) and to the slow global rotational motion
(τg). Importantly, GdL displays a relaxivity similar to that of the
double chain chelates, despite a lower global rotational
correlation time (τg = 3780 vs. 5206 and 4700 ps for
Gd[(C18)2DOTAda)] and Gd[(DOTA(GAC12)2)], respectively) and
a substantially lower degree of coupling of global and local
rotational motions (higher flexibility) (S2 = 0.24 vs. 0.78 and
0.70 for Gd[(C18)2DOTAda)] and Gd[(DOTA(GAC12)2)], respecti-
vely). Importantly, the relaxivity of the double chain chelates
is limited by slow water exchange (k298ex /10
7 = 6.2 vs. 0.30 and
0.34 s−1 for GdL and Gd[(C18)2DOTAda)] and Gd[(DOTA-
(GAC12)2)], respectively).
The high relaxivity attained by GdL can be thus ascribed to
simultaneous optimization of τR and kex. The optimization of
the rotational dynamics of complexes has been firmly estab-
lished for relaxivity enhancement at intermediate fields. The
simultaneous optimization of τR and kex is far more demand-
ing and often achieved at the expense of complex stability
compromising potential biological applications. This study
highlights the importance of simultaneous optimization of all
molecular parameters in order to attain high relaxivities and
provides further support for our claim that amide conjugates
of the DO3A-N-α-aminopropionate chelator are valuable
synthons for constructing high relaxivity safe CA for MRI.
Luminescence studies
The Gd[(DO3A-N-(α-pyrenebutanamido)propionate)] complex
was designed as a bimodal MRI/fluorescence probe. The
pyrene fluorophore was selected to impart self-assembly
Fig. 3 1H nuclear magnetic relaxation dispersion (NMRD) profiles of
GdL in the monomer state at 0.3 mM at 25 °C (▲) and 37 °C (■). The
curves represent results from the fittings as described in the text.
Fig. 4 Structure of amphiphilic DOTA-type ligands compared in Table 2
and discussed in the text.
Table 2 Molecular parameters for amphiphilic DOTA-type complexes
Chelate
MW
(g mol−1)
cmc
(mM)
τ298l
(ps)
τ298g
(ps) S2
k298ex
(/107 s−1)
rm1 ,
f
(mM−1 s−1)
GdL1
a 881.2 0.06 330 2810 0.28 0.48 20.7
GdL2
b 881.2 — 271 2696 0.21 8.12 24.2
GdL3
c 1036 <0.1 820 4700 0.70 0.34 34.8
GdL4
d 1285 0.004 135 5206 0.78 0.30 35
GdLe 857 0.6 930 3780 0.24 6.2 32.2
a Ref. 37. b Ref. 38. c Ref. 40. d Ref. 39. e This work. f (20 MHz, 25 °C).
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properties and concentration-dependent fluorescence report-
ing capability to the paramagnetic complex.27
The absorption (Fig. S6†) and the fluorescence emission
properties (Fig. S7†) of the free ligand L and the GdL complex
were studied in non-deoxygenated water (pH 7.0) at con-
centrations well below the cmc by UV-Vis and steady-state fluo-
rescence spectroscopy (Table 3).
At concentrations below the cmc (cmc = 2.7 mM for L,
see below, and 0.6 mM for GdL), L and GdL display similar
absorption spectra in the region characteristic of pyrene
(300–350 nm) assigned to intraligand π–π* transitions.32 Selec-
tive irradiation of the pyrene chromophore on L and GdL at
345 nm yields fluorescence spectra displaying vibronically
structured features, assigned to intraligand 1π–π* transitions,
characteristic of pyrene monomer emission (Fig. S5†).32,41At
the concentration studied (well below the cmc), no excimer
emission (broad featureless band with an emission with an
apparent maximum located at 490–500 nm) was observed for
both the free ligand and the Gd3+ complex. The fluorescence
quantum yields for L and for the pyrene-centred emission in
GdL are of the same order of magnitude as those reported for
other pyrene conjugates.
Complex formation with paramagnetic Gd3+ seems to have
only a minor effect on the fluorescence quantum yield of L.41
We envisaged that it could be possible to monitor the self-
assembly process of L and GdL by taking advantage of the
aggregation-sensitive fluorescence properties of the pyrenyl
moiety.27 With this aim, we studied by steady-state fluo-
rescence the effect of the concentration on the fluorescence
properties of L (Fig. S7†) and GdL (Fig. 5).
For low micromolar concentrations of L and GdL, the fluo-
rescence spectra display the characteristic vibronically struc-
tured pyrene monomer emission band. For higher (low
millimolar) concentrations, the intensity of the monomer
emission band is reduced and a new broad, red-shifted,
featureless band, assigned to excimer formation, appears. The
concentration dependence of the ratio of fluorescence emis-
sion intensity for the excimer (490 nm) and for the monomer
(377 nm) (IE/IM) was used to determine independently the cmc
for L (Fig. S7†) and GdL (Fig. 5) by fitting the experimental
data points to a sigmoidal curve model (Table S1†).42,43 A cmc
value of approximately 0.64 mM, in excellent agreement with
the value determined by relaxometry (0.60 mM), was derived
for GdL from the fluorescence study (Fig. 5). A much higher
cmc value (2.7 mM) was determined for the free ligand
(Fig. S7†), reflecting the ionization state (multi-charged) of the
free metal chelator. Below the cmc, the ligand and the
complex are molecularly dissolved and the fluorescence arises
from the decay of excited monomers. Above the cmc, fluo-
rescence emission arises predominantly from the decay of
excited dimers – excimers. Higher concentrations of GdL
increase the number of micelles and enhance excimer for-
mation and the corresponding fluorescence emission inten-
sity. Two different mechanisms have been established for
excimer emission: diffusive encounter of an excited monomer
with a ground state molecule and the direct excitation of (pre-
associated) ground state dimers. The partitioning of the
different modes of excimer formation depends on the fluidity
of the micelle environment. Time-resolved fluorescence experi-
ments suggest that the diffusive mechanism is the main con-
tributor to excimer formation in cationic gemini surfactants
containing a pyrene moiety and a long alkyl chain.44 The order
parameter determined for the micellar form of GdL (S2 = 0.24)
indicates that the micelles are fluid, suggesting that the
diffusive mechanism might be responsible for excimer for-
mation. Deciphering the mechanism of excimer formation in
GdL micelles is outside the scope of the present study. The
pyrene-centered fluorescence of GdL effectively provides this
complex with MRI/fluorescence bimodal imaging agent
activity. From a practical point of view, the pyrene centred fluo-
rescence of GdL could be used for imaging studies in small
Fig. 5 Normalized fluorescence spectra for GdL in non-deoxygenated
water over the concentration range 1 × 10−7–5 × 10−3 M (λexc = 345 nm).
Inset – changes in the emission properties of GdL as the ratio of the flu-
orescence emission intensity for the excimer (IE, 490 nm) and for the
monomer (IM, 377 nm) (IE/IM) as a function of GdL concentration.
Table 3 Maximum absorption (λabs) and emission wavelengths (λem),
molar extinction coefficients (ε) and fluorescence quantum yields (ΦF)
for ligand L and GdL complex (λex 345 nm) in non-deoxygenated water
at concentrations below the cmc
λabs
b (nm)
(ε/104 M−1 cm−1) λem (nm) ΦF
a,c
L GdL L GdL L GdL
344 (3.26) 344 (4.43)
328 (2.35) 328 (3.20)
377 377
314 (1.00) 314 (1.59)
397 398 0.22 0.17
277 (3.60) 277 (5.59)
417 418
266 (2.05) 266 (3.78)
243 (5.62) 243 (9.19)
a Relative to anthracene in ethanol (Φ = 0.27). b Ligand and complex at
1 × 10−5 M concentration. c Ligand and complex at 1 × 10−6 M
concentration, non-deoxygenated solutions.
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animal models, for ex vivo characterization of tissue distri-
bution, cell internalization and intracellular chelate localiz-
ation and studies with cell lines.45
Lanthanide centred fluorescence in the visible (Eu3+ and
Tb3+) and in the NIR region (Nd3+, Yb3+) is well suited for bio-
logical imaging for the following reasons: enhanced light
penetration into biological tissues (especially in the NIR
region); elimination of interference from tissue auto-fluo-
rescence using time-gating techniques; long wavelength exci-
tation, far into the visible region. Very low molar absorptivities
(f–f transitions are forbidden by Laporte’s and parity rules)
make the direct excitation of Ln3+ ions impracticable. The for-
mation of emissive Ln3+ excited states requires sensitization by
sensitizing groups that absorb excitation light and transfer the
resulting energy to the Ln3+ excited states (antenna effect),
usually through ligand-centred triplet excited states.46 In this
study, we tested the possibility of using the pyrene chromo-
phore to sensitize near infrared emitting Ln3+ ions in the
corresponding LnL complexes (Ln = Nd and Yb) (Fig. 6).
Emission spectra of the NdL and YbL complexes under
ligand excitation exhibit metal-centred NIR emission bands at
ca. 1064 nm (4F3/2 →
4F13/2) for NdL and a band with an appar-
ent maximum at ca. 1000 nm (2F5/2 →
2F7/2) for YbL.
31,32 The
excitation spectra for both luminescent Nd3+ and Yb3+ com-
plexes are similar to each other and match well the profile of
the corresponding absorption spectra as an indication that the
sensitization of the lanthanide luminescence is occurring
through the same electronic levels centred on pyrene.
Interaction of GdL with human serum albumin (HSA)
Self-assembly of chelates into supramolecular structures (as
discussed in this work) and binding to serum albumin (HSA)
are robust strategies to enhance chelate relaxivity via optimiz-
ation of τR. In addition to relaxivity enhancement, self-assem-
bly and binding of chelates to HSA slow down CA leakage into
the interstitial compartment, providing an extended time
window for vasculature imaging (MRI angiography).47 The
binding affinity of GdL to HSA was assessed by Proton Relax-
ation Enhancement (PRE) measurements. The PRE methods
are tailored to determine the differences in the NMR water
solvent relaxation rates between protein-bound (resulting in an
increase of the relaxation rates) and free substrates. Experi-
mentally, it consists of measuring the water proton relaxation
rates Robs1 in solution at increasing concentrations of the
protein while keeping the concentration of the metal chelate
constant (E-titration) or vice versa (M-titration). The data
obtained for the E-titration using a GdL concentration below
the cmc (0.1 mM) and increasing HSA concentrations (Fig. 7)
were fitted to a one site binding model (eqn (S1)†).
The fitting affords an estimation of the relaxivity of the
HSA-bound form, rc1 (53.1 ± 6.7 and 47.0 ± 5.6 mM
−1 s−1 at 25
and 37 °C, respectively), and an apparent HSA-GdL association
constant, KA (KA = 1/Kd) ((1.9 ± 0.1) × 10
3 and (1.7 ± 0.1) × 103
M−1 at 25 and 37 °C, respectively). These values correspond to
binding affinities similar to Gd(BOPTA)2− but weaker than
those for MS-325, two blood pool agents presenting strong
HSA binding.48 Under the limiting E-titration conditions
([GdL] = 0.1 mM and [HSA] = 4%), the fraction of bound
chelate can be estimated as higher than 90%. These values are
in line with those reported recently by Caravan for similar
amide conjugates.12 It is known that HSA has multiple
binding sites. Among the many studies published on HSA
binding of Gd3+ complexes, typically those involving ultrafiltra-
tion experiments have reported binding to more than one
independent site with different binding constants.49,50 Those
stepwise binding constants show that one binding site is
much stronger than the others, justifying the common use of a
Fig. 6 Absorbance (black), excitation (λem = 1064 nm, violet) and emis-
sion (λexc = 344 nm, red) spectra for the NdL complex (a) and YbL
complex (b) in water.
Fig. 7 Proton relaxation enhancement data (20 MHz, pH 7.4) to assess
HSA binding of GdL: E-titration at 0.1 mM GdL concentration at 25 °C
and 37 °C.
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1 : 1 binding isotherm in interpreting the relaxometric data for
albumin binding of Gd3+ complexes.51 In fact, most often
relaxometric data alone do not allow for distinguishing
between different binding models. An independent evaluation
of KA and n may be, in principle, pursued through the analysis
of the data obtained from an M-titration, in which a fixed con-
centration of HSA is titrated with the Gd3+ complex. The titra-
tion of 4% HSA with GdL is restricted to the narrow range of
concentrations below cmc precluding a quantitative analysis of
the data. The interaction of GdL with HSA is prone to modu-
late the biodistribution of GdL as recently reported for similar
conjugates.12,52
Biodistribution studies
The biodistribution profile of GdL was obtained after 1 and
24 hours post-injection (pi) using the 153Sm3+-labelled surro-
gate complex (Fig. 8 and Table S2†).
A recent patent claims that peptides derivatised with pyrene
are able to cross the blood–brain barrier thanks to (presum-
ably) a correct lipophylicity/hydrophylicity balance imparted by
the pyrene moiety.53 This intriguing possibility was considered
during the biodistribution study. The 153SmL chelate displays
biodistribution profiles at 1 and 24 hours pi similar to other
micellar systems.54 After 1 hour pi there is substantial activity
in the blood, liver, spleen and lungs. The high activity in the
blood after 1 hour pi reflects the micellar nature of the CA and
its strong association with HSA, which slows down leakage of
the complex into the interstitial compartment. The complex
follows both hepatic and renal elimination. The hepatic and
spleen uptake reflects the micellar nature of the CA and the
role played by resident macrophages in the liver and spleen
(Reticulo Endothelial System, RES) in clearing particulate
material from the blood. The activity in the lungs might again
reflect the retention of particulate material in narrow blood
vessels and the extensive vascularisation of that organ and
thus the high blood content of the lungs. The increase in
activity in the spleen and liver after 24 hours pi correlates with
the activity clearance from the blood and lungs, suggesting
particle retention on those organs. Interestingly, after 1 hour
pi, a low activity is measurable in the brain/cerebellum,
suggesting that the complex might cross the blood–brain
barrier. This possibility deserves further investigation.
Conclusions
The pyrenebutyric acid conjugate of the DO3A-N-(α-amino)pro-
pionate chelator was synthesised following synthetic methodo-
logies reported previously by us. The lipophilic pyrene moiety
imparts a concentration-dependent self-assembly ability (pre-
sumably into micelles) to the Gd[(DO3A-N-(α-pyrenebutan-
amido)propionate)] chelate. The aggregated form of the Gd3+
chelate displays high relaxivity thanks to simultaneous optim-
ization of the rotational correlation time and of the water
exchange rate. Nonetheless, the relaxivity is still limited by
internal flexibility. The Gd3+ complex displays pyrene-centred
fluorescence properties sensitive to its aggregation state. The
Nd3+ and Yb3+ complexes exhibit lanthanide-centred sensitized
NIR emission. The surrogate 153Sm3+ complex displays a bio-
distribution profile similar to other micellar systems. Interest-
ing applications of this probe can be based on the recent
report that carbon-based nanomaterials (graphene, graphene
oxide, carbon nanotubes) functionalized non-covalently with
pyrene conjugates are promising for the development of exqui-
site probes for biological processes.55 In summary, we have
reported recently that Gd3+ complexes of amide conjugates of
the DO3A-N-(α-amino)propionate chelator are new leads for
targeted, high relaxivity, safe CA for in vivo MRI.21 In this work
we provide further evidence to support this claim using simple
design principles and robust chemistry accessible to all
laboratories.
Experimental
Materials and methods
Chemicals were purchased from Sigma-Aldrich and used
without further purification. Solvents used were of reagent
grade and purified by usual methods. Cyclen was purchased
from CheMatech, France. Reactions were monitored by TLC on
Kieselgel 60 F254 (Merck) on an aluminium support. Detection
was done by examination under UV light (254, 365 nm) and by
adsorption of iodine vapour. Flash chromatography was per-
formed on a Kieselgel 60 (Merck, mesh 230–400). The relevant
fractions from flash chromatography were pooled and concen-
trated under reduced pressure, T < 313 K. Ion exchange
chromatography was performed on Dowex 1X2-100-OH− resin
(Sigma Aldrich). The resin was purchased as the Cl− form and
converted to the OH− form by treatment with aqueous NaOH.
1H and 13C NMR spectra (assigned by 2D DQF-COSY and
HMQC techniques) were run on a Varian Unity Plus 300 NMR
spectrometer, operating at 299.938 MHz and 75.428 MHz, for
1H and 13C, respectively. Chemical shifts (δ) are given in ppm
relative to the CDCl3 solvent (
1H, δ 7.27; 13C, δ 77.36) as an
internal standard. For 1H and 13C spectra recorded in D2O,
chemical shifts (δ) are given in ppm relative to TSP as the
Fig. 8 Biodistribution, stated as a percentage of injected dose per gram
of organ (%ID/g), of 153SmL in Wistar rats 1 and 24 hours after i.v. injec-
tion. Results are the mean of 4 animals.
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internal reference (1H, δ 0.0) and tert-butanol as the external
reference (13C, CH3 δ 30.29).
Synthesis of methyl 3-hydroxy-2-(4-(pyren-1-yl)butanamido)-
propanoate (3). To a solution of HCl, H-Ser-OMe (1)
(5.0 mmol, 0.778 g) and triethylamine (10 mmol) in aceto-
nitrile (5.0 mL) were added 1-pyrenebutyric acid (2) (5.0 mmol,
1.44 g), 1-hidroxybenzotriazole (HOBt) (5.0 mmol, 0.675 g)
and dicyclohexylcarbodiimide (DCC) (5.5 mmol, 1.13 g). The
reaction mixture was left stirring at room temperature for
18 hours. The reaction mixture was filtered and the solvent
was removed under reduced pressure. The residue was dis-
solved in ethyl acetate (100 mL), washed with KHSO4 1 M,
NaHCO3 1 M and brine (3 × 30 mL each) and dried over
MgSO4. The solvent was removed to give 3 (1.70 g, 87%) as a
yellow oil. 1H NMR (300 MHz, CDCl3): δ = 2.17–2.26 (m, 2H,
CH2), 2.37 (t, J = 7.2 Hz, 2H, CH2), 3.35–3.41 (m, 2H, CH2),
3.76 (s, 3H,CH3), 3.86–4.00 (m, 2 H, β-CH2 Ser), 4.66–4.71 (m,
1 H, α-CH Ser), 6.49 (d, J = 7.2 Hz, 1H, NH), 7.84 (d, J = 7.8 Hz,
1H, ArH), 7.96–8.02 (m, 3H, ArH), 8.08–8.17 (m, 4H, ArH), 8.28
(d, J = 9.3 Hz, 1H, ArH) ppm. 13C NMR (75.4 MHz, CDCl3): δ =
27.14 (CH2), 32.58 (CH2), 35.69 (CH2), 52.72 (CH3), 54.61 (CH),
63.40 (CH2), 123.28 (CH), 124.74 (CH), 124.75 (CH), 124.88
(CH), 124.91 (C), 125.02 (C), 125.81 (CH), 126.68 (CH), 127.33
(CH), 127.37 (CH), 127.42 (CH), 128.70 (C), 129.91 (C), 130.82
(C), 131.24 (C), 135.61 (C), 170.93 (CvO), 173.20 (CvO) ppm.
HRMS (ESI): m/z: calcd for C24H23NNaO4, [M + Na]
+: 412.1520;
found 412.1519.
Synthesis of methyl 2-[N-(tert-butoxycarbonyl)-4-(pyren-1-yl)-
butanamido]acrylate (4). To a solution of Pyr-Ser-OMe (3)
(5.0 mmol, 1.95 g) in dry acetonitrile (5.0 mL) were added
4-dimethylaminopyridine (DMAP) (1.7 mmmol, 0.213 g) and
tert-butyldicarbonate (17.5 mmol, 3.82 g). The reaction mixture
was left stirring at room temperature for 24 hours. The solvent
was removed under reduced pressure and the residue was dis-
solved in ethyl acetate (100 mL). The organic layer was washed
with KHSO4 1 M, NaHCO3 1 M and brine (3 × 30 mL, each),
dried over MgSO4 and the solvent removed under reduced
pressure to give 4 (1.91 g, 81%) as a yellow oil. 1H NMR
(400 MHz, CDCl3): δ = 1.46 (s, 9 H, CH3 Boc), 2.23–2.27 (m, 2H,
CH2), 3.17 (t, J = 6.8 Hz, 2H, CH2), 3.42–3.46 (m, 2H, CH2),
3.81 (s, 3H, OCH3), 5.67 (s, 1H, CH2), 6.48 (s, 1H, CH2), 7.91
(d, J = 7.6 Hz, 1H, ArH), 7.98–8.06 (m, 3H, ArH), 8.11–8.13 (m,
2H, ArH), 8.16–8.18 (m, 2H, ArH), 8.37 (d, J = 9.2 Hz, 1H, ArH)
ppm. 13C NMR (100.6 MHz, CDCl3): δ = 26.82 (CH2), 27.81
[C(CH3)3], 32.91 (CH2), 37.44 (CH2), 52.47 (OCH3), 83.72
[OC(CH3)3], 123.56 (CH), 124.67 (CH), 124.77 (CH), 124.79
(CH2), 124.99 (C), 125.06 (C), 125.74 (CH), 125.90 (CH), 126.58
(CH), 127.29 (CH), 127.34 (CH), 127.47 (CH), 128.77 (C), 129.88
(C), 130.93 (C), 131.40 (C), 135.55 (C), 136.29 (C), 151.52
(CvO), 163.68 (CvO), 175.21 (CvO) ppm. HRMS (ESI): m/z:
calcd for C29H29NNaO5, [M + Na]
+: 494.1943; found 494.1929.
Synthesis of (2-(N-t-butoxycarbonyl)pyrenebutyramido)-
methoxycarbonylethyl-1,4,7,10-tetrazacyclododecane (mono-
alkylated cyclen) (6). K2CO3 (1.47 g, 10.6 mmol) was added to
a solution of cyclen (5) (0.460 g, 2.67 mmol) in MeCN (30 mL).
To this solution was added (pyrene)Boc-Δ-AlaOMe (4) (0.840 g,
1.78 mmol). The suspension was vigorously stirred at room
temperature for 5 hours. The suspended solid was removed by
filtration and the solvent was evaporated under reduced
pressure. The residue was purified by flash chromatography
(100% CH2Cl2 → CH2Cl2–EtOH–NH4OH–H2O (50 : 50 : 1 : 1)) to
afford compound 6 as a viscous light yellow oil (0.95 g, 83%).
1H NMR (300 MHz, CDCl3): δ = 1.47 (s, 9H, Boc), 2.20 (m, 2H,
CH2CH2CH2), 2.50–2.80 (m, 16H, N(CH2)2N-cyclen), 3.01–3.18
(m, 2H, C(O)CH2CH2), 3.38–3.50 (m, 2H, CH2CH2-Pyrene), 2.77
(dd, J = 14.4 and 6.9 Hz, 1 H, NCHaHbCH), 3.38 (dd, J = 14.25
and 5.1 Hz, 1 H, NCHaHbCH), 3.70 (s, 3H, OMe), 5.51 (t, J = 6.9
and 4.8 Hz, 1H, NCHaHbCH), 7.85–8.40 (9H, m, Ar).
13C NMR
(75.4 MHz, CDCl3): δ = 26.98 (βCH2-Ser), 27.88 (C(CH3)3), 32.85
(γCH2), 37.79 (αCH2), 45.02 (CH2), 45.37 (CH2), 46.75 (CH2),
51.22 (CH2), 52.22 (OCH3), 53.52 (CH), 55.97 (NCH2CH), 84.31
(C(CH3)3), 123.41 (CH-Ar), 124.70 (CH-Ar), 124.72 (CH-Ar),
124.87 (CH-Ar), 125.83 (CH-Ar), 126,67 (CH-Ar), 127.37 (2 ×
(CH-Ar)), 127.45 (CH-Ar), 128.01 (C-Ar), 128.62 (C-Ar), 129.86
(C-Ar), 130.82 (C-Ar), 131.31 (C-Ar), 136.13 (C-Ar), 151.86 (NC-
(O)), 170.63 (C(O)OCH3), 175.37 (C(O)CH2). HRMS (ESI): m/z:
calcd for C37H50N5O5, [M + H]
+: 644.3812, found: 644.3807.
Synthesis of 2-pyrenebutyramido-methoxycarbonylethyl-
4,7,10-tris-(ethoxycarbonylmethyl)-1,4,7,10 tetrazacyclododecane
(tetraalkylated cyclen) (7). A solution of monoalkylated
cyclen (6) (0.860 g, 1.33 mmol) in trifluoroacetic acid in
dichloromethane (60%, 25 mL) was stirred overnight at room
temperature. The solvent was evaporated at reduced pressure
and the residue was re-dissolved in dichloromethane. This pro-
cedure was repeated several times to give a light yellow thick
oil. 1H NMR spectroscopy (CDCl3) revealed the disappearance
of the signal assigned to the tert-butyloxycarbonyl group in
compound 6. K2CO3 (2.20 g, 15.96 mmol) was added to a solu-
tion of deprotected 6 (1.33 mmol, quantitative deprotection
was assumed) in MeCN (30 mL). To this suspension was added
ethyl bromoacetate (0.55 mL, 4.66 mmol). The suspension was
vigorously stirred at room temperature for 2.5 hours. The solid
in suspension was removed by filtration, the solvent was evap-
orated under reduced pressure and the residue was purified by
flash chromatography (100% CH2Cl2→ CH2Cl2–EtOH (1 : 1)) to
afford compound 7 (0.632 g, 59%) as a white foam. 1H NMR
(300 MHz, CDCl3): δ = 1.26 (m, 9H, 3 × CH2CH3), 2.20 (m, 2H,
CH2CH2CH2), 2.56 (m, 2H, C(O)CH2CH2), 2.60–2.90 (m, 6H,
NCH2C(O)), 2.90–3.70 (m, 16H, N(CH2)2N), 3.37 (m, 2H,
CH2CH2 Pyrene), 3.73 (s, 3H, OMe), 3.92 (bd, 2H, NCH2CH),
4.09 (m, 6 H, CH2CH3), 4.94 (bd, 1H, NCH2CH), 7.80–8.40 (9H,
m, Ar). 13C NMR (75.4 MHz, CDCl3): selected signals: 13.84,
13.88, 14.05 (CH2CH3), 27.36 (βCH2-Ser), 32.79 (γCH2), 35.45
(αCH2), 48.21 (CH), 48.91 (CH2), 50.34 (CH2), 51.36 (CH2),
52.47 (OCH3), 53.01 (CH2), 53.60 (CH2CH), 54.90 (CH2), 55.19
(CH2), 55.71 (CH2), 55.98 (CH2), 58.25 (CH2), 60.51 (CH2),
60.99, 61.20, 61.55 (OCH2), 123.63 (CH-Ar), 124.62 (CH-Ar),
124.75 (CH-Ar), 124.85 (CH-Ar), 125.76 (CH-Ar), 126.51
(CH-Ar), 127.18 (CH-Ar), 127.41 (CH-Ar), 127.46 (CH-Ar),
128.67 (C-Ar), 129.72 (C-Ar), 130.87 (C-Ar), 131.32 (2 × (C-Ar)),
136.43 (C-Ar), 136.53 (C-Ar), 170.312 (C(O)OCH3), 170.53 (C(O)-
OCH2), 173.15 (C(O)OCH2), 173.55 (C(O)OCH2), 174.31 (NC-
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(O)). HRMS (ESI): m/z: calcd for C44H60N5O9, [M + H]
+:
802.4391, found: 802.4386.
Synthesis of 2-pyrenebutyramido-carboxyethyl-4,7,10-tris-
(carboxymethyl)-1,4,7,10-tetrazacyclododecane (L) (DO3A-N-
(α-pyrenebutyramido)propionate metal chelator). Compound
(7) (0.566 g, 0.710 mmol) was dissolved in a mixture made up
of 20 mL of water and 20 mL of ethanol. The solution was
adjusted to pH 10–11 by adding small portions of Dowex 1X2-
100-OH− resin. The suspension was kept stirring at room
temperature for 2 hours. The wet resin was transferred into a
chromatography column, washed with water (∼50 mL) and
eluted with 0.1 M hydrochloric acid, followed by a mixture of
hydrochloric acid 0.1 M–ethanol (1 : 1). The relevant fractions,
identified by TLC (ethanol–water 1/1, detection using iodine
vapour and analysis under UV light at 365 nm), were pooled,
concentrated at room temperature and further dried under
vacuum to afford the final compound, as a hydrochloride, as a
light yellow solid (0.31 g, 62%). 1H NMR (300 MHz, D2O/
MeOD): δ = 2.13 (bb, 2H, CH2CH2CH2), 2.50 (m, 2H, C(O)-
CH2CH2), (2.9–3.6, broad, overlapped signals with an inte-
gration corresponding to 18H, 4 × N(CH2)2N and NCH2CH),
3.33 (m, 2H, CH2CH2Pyrene), 3.81 (broad, overlapped signals
with an integration corresponding to 6H, NCH2), 4.76 (m (br),
1H, CH), 7.80–8.40 (9H, m, Ar). 13C NMR (75.4 MHz, D2O/
MeOD): selected signals: 28.22 (βCH2), 33.25 (γCH2), 36.29
(αCH2), 50.49 (bb, CH2), 54.95 (bb, CH2), 124.31 (CH-Ar),
125.44 (C-Ar), 125.54 (C-Ar), 125.75 (CH-Ar), 125.85 (2 ×
(CH-Ar)), 127.08 (CH-Ar), 127.50 (CH-Ar), 127.08 (C-Ar), 128.18
(CH-Ar), 128.37 (CH-Ar), 128.46 (CH-Ar), 129.41 (C-Ar), 130.75
(C-Ar), 131.75 (C-Ar), 137.27 (C-Ar), 177.47 (NC(O)). HRMS
(ESI): m/z: calcd for C37H46N5O9, [M + H]
+: 704.3296, found:
704.3290.
1H and 17O NMR and 1H NMRD experiments
Sample preparation. To an aqueous solution of the ligand
(pH 5) was added drop-wise an aqueous solution of the corres-
ponding LnCl3·xH2O salt in a 1 : 1 mole ratio. The solution was
stirred at room temperature over 1 hour while keeping its pH
at around 5.7 by adding aqueous NaOH. The solution was left
stirring at room temperature overnight. Concentration under
reduced pressure afforded off-white solids. Solutions for NMR
measurements (20 mM) were obtained by dissolution of appro-
priate amounts of solid complexes in D2O (V = 0.75 mL).
Proton 1D spectra of paramagnetic (Sm3+ and Eu3+) and dia-
magnetic (La3+) complexes were obtained at 298 K on a Varian
VNMRS 600 (14.09 T, 600.14 MHz) NMR spectrometer.
The GdL complex solutions for 17O NMR and 1H NMRD
experiments were prepared by mixing equimolar amounts of
GdCl3 and the ligand. A slight excess (5%) of the ligand was
used. The solution was stirred at room temperature over
1 hour while keeping its pH at around 5.7 by adding aqueous
NaOH. The solution was left stirring at room temperature over-
night. The absence of free metal was checked by the xylenol
orange test.56,57 The pH of the stock solution was adjusted to
the desired value by adding aqueous NaOH (0.1 mM). 17O-
enriched water (17O: 11.4%) was added to the solutions for 17O
measurements to improve the sensitivity. The final concen-
tration of the complex solution was 17.56 mmol kg−1 at pH =
6.90. For the NMRD experiments 5.0 mM and 0.1 mM solu-
tions of the complex at pH 6.98 were used.
17O NMR experiments
Variable-temperature 17O NMR measurements were performed
using a Bruker Avance-500 (11.7 T) spectrometer. A BVT-3000
temperature control unit was used to stabilize the temperature,
measured by a substitution technique. The samples were
sealed in glass spheres that fitted into 10 mm o.d. NMR tubes
to eliminate susceptibility corrections to the chemical shifts.58
Longitudinal relaxation rates (1/T1) were obtained by the inver-
sion recovery method, and transverse relaxation rates (1/T2) by
the Carr–Purcell–Meiboom–Gill spin-echo technique. Acidified
water, pH 3.4, was used as the external reference.
NMRD measurements
The measurements were performed using a Stelar Spinmaster
FFC NMR relaxometer (0.01–20 MHz) equipped with a VTC90
temperature control unit. At higher fields, the 1H relaxivity
measurements were performed on a Bruker electromagnet at
frequencies of 30 MHz, 40 MHz, 60 MHz and 80 MHz. In each
case, the temperature was measured by a substitution tech-
nique. Variable temperature measurements were performed at
25 and 37 °C.
Relaxivity studies of pH dependence and Zn2+ transmetallation
The transmetallation reaction of GdL with Zn2+ was studied by
following the time dependent decrease of the water proton
longitudinal relaxation rate, R1, of a phosphate-buffered saline
solution (PBS, pH 7.1, 10 mM) containing 1.5 mM of GdL after
adding an equimolar amount of ZnCl2 while the sample was
vigorously stirred.59 The water longitudinal relaxation rate was
also measured as a function of time on the PBS buffered solu-
tion (pH 7.1, 10 mM) containing 2.5 mM GdL.60 The pH
dependence of the relaxivity of the GdL solution was studied
by adjusting (pH meter) the pH of a 1 mM solution of GdL in
water with either NaOH or HCl solutions using a pH meter. A
Bruker Minispec mq20 (20 MHz, 298 K) relaxometer was used
for all measurements.
Fluorescence measurements
The absorption and the ligand-based fluorescence emission
spectra of the free ligand L and the GdL complex were
recorded, respectively, using a Jasco V-630 UV-Vis spectrophoto-
meter and a HORIBA JobinYvon Fluoromax-4 spectrofluori-
meter, equipped with a monochromator in both excitation and
emission and a temperature controlled cuvette holder. Fluo-
rescence spectra were corrected for the instrumental response
of the system.
The fluorescence quantum yields (Φs) were determined
using a standard method.61,62 Anthracene in ethanol (Φr =
0.27)63 was used as the reference.
For lanthanide centred fluorescence studies in the visible
(Eu3+ and Tb3+) and in the NIR region (Nd3+, Yb3+), absorbance
Dalton Transactions Paper
This journal is © The Royal Society of Chemistry 2014 Dalton Trans., 2014, 43, 3162–3173 | 3171
Pu
bl
ish
ed
 o
n 
17
 D
ec
em
be
r 2
01
3.
 D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
id
ad
e 
de
 C
oi
m
br
a 
on
 0
2/
04
/2
01
4 
16
:2
6:
25
. 
View Article Online
UV spectra were performed on a Uvikon spectrophotometer,
while emission and excitation (lanthanide luminescence)
spectra were measured using a modified Jobin-Yvon Horiba
Fluorolog-322 spectrofluorimeter equipped with a Hamamatsu
R928 detector (for the visible domain) and a DSS-IGA020L
(Electro-Optical Systems, Inc.) detector (for the NIR domain).
Luminescence and excitation spectra were corrected for vari-
ations in lamp output, the non-linear response of the detector
and the use of neutral density filters (where applicable). For
collecting luminescence data, samples were placed in quartz
Suprasil cells (Hellma® 115F-QS, bandpass 0.2 cm).
Biodistribution studies
153SmL for in vivo experiments was prepared by adding 1 mCi
of [153Sm]Cl3 (produced at the Instituto Tecnológico e Nuclear,
Lisbon, Portugal with a specific radioactivity >5 GBq mg−1) to
a solution of 1 mg of the chelator in acetate buffer (400 μL,
0.4 M, pH 5) and heated at 80 °C for ca. 1 hour. The radio-
chemical purity of 153SmL1 was determined by TLC. The per-
centage of chelated metal was found to be greater than 95%.
Groups of four animals (Wistar male rats weighing
ca. 200 g) were anaesthetized with ketamine (50.0 mg mL−1)/
chloropromazine (2.5%) (10 : 3) and injected in the tail vein
with ca. 100 μCi of the tracer. Animals were sacrificed 1 and
24 hours later and the major organs were removed, weighed
and counted in a γ well-counter.
Size distribution
The size distribution of particles in a (micellar) solution of
GdL at a concentration well above the cmc (5.0 mM, pH 7.0)
was determined with a Malvern Zetasizer, NANO ZS (Malvern
Instruments Limited, UK) using an He–Ne laser (λ = 633 nm)
and a detector angle of 173°. The GdL solution in a polystyrene
cell (1 mL) was analysed at 25 °C. The mean hydrodynamic
radius (z-average) and a width parameter for the distribution,
polydispersity or polydispersity index (PdI) were calculated
from the intensity of the scattered light. In the present work,
the intensity-based z-average parameter was considered the
best approach to the actual particle size.
Data analysis
Data obtained from 17O NMR, 1H NMRD, Luminescence and
Quantum Yield measurement studies were processed using
OriginLab Pro 8 SRO. Data from relaxometric and transmetal-
lation studies were processed using Microsoft Office Excel
2007.
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